Cornelissen, Robin

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 2,298

First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial

Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 1,215

Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma

Cornelissen, R., Lievense, L. A., Maat, A. P., Hendriks, R. W., Hoogsteden, H. C., Bogers, A. J., Hegmans, J. P., & Aerts, J. G. (2014) · PLoS ONE

Occupational and environmental lung diseasesImmune cells in cancer

Cited by 91

Virtual reality and artificial intelligence for 3-dimensional planning of lung segmentectomies

Sadeghi, A. H., Maat, A. P. W. M., Taverne, Y. J. H. J., Cornelissen, R., Dingemans, A.-M. C., Bogers, A. J. J. C., & Mahtab, E. A. F. (2021) · JTCVS Techniques

Anatomy and Medical TechnologyAugmented Reality Applications

Cited by 89

Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy

Noordam, L., Kaijen, M. E. H., Bezemer, K., Cornelissen, R., Maat, L. A. P. W. M., Hoogsteden, H. C., Aerts, J. G. J. V., Hendriks, R. W., Hegmans, J. P. J. J., & Vroman, H. (2018) · OncoImmunology

T-cell and B-cell ImmunologyOccupational and environmental lung diseases

Cited by 52